Global Transarterial Chemoembolization (TACE) Market Strategic Research Report

Scope of the Report

The global Transarterial Chemoembolization (TACE) market size is predicted to grow from US$ 13,310 million in 2025 to US$ 23,400 million in 2032; it is expected to grow at a CAGR of 8.6% from 2026 to 2032.

Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.

The global Transarterial Chemoembolization (TACE) market refers to the market for a minimally invasive procedure used in the treatment of liver cancer. TACE is a locoregional therapy that combines chemotherapy and embolization to deliver anticancer drugs directly to the tumor site while blocking the blood supply to the tumor.

Liver cancer, specifically hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths worldwide. TACE has emerged as a commonly used treatment option for patients with intermediate-stage HCC or those who are not eligible for surgical resection or liver transplantation.

The TACE procedure involves the insertion of a catheter into the hepatic artery, the main blood supply to the liver. Through the catheter, a drug-eluting bead or emulsion containing chemotherapeutic agents is infused directly into the tumor, followed by the injection of embolic agents to occlude the blood vessels feeding the tumor. This dual action targets the tumor cells and restricts their blood supply, thereby delaying tumor growth and potentially shrinking the tumor.

Some key factors driving the global TACE market include:

Increasing incidence of liver cancer: The rising prevalence of liver cancer, particularly HCC, has led to an increased demand for effective treatment options. TACE offers a targeted approach for patients with intermediate-stage HCC, who represent a significant portion of liver cancer cases.

Limited surgical options: Liver resection and transplantation remain the most effective treatment options for early-stage HCC. However, many patients are not eligible for surgery due to the size and location of the tumor, underlying liver disease, or other patient factors. TACE provides a non-surgical alternative for these patients.

Advancements in imaging and catheterization techniques: The advancements in imaging technologies, such as computed tomography (CT) and fluoroscopy, have improved the precision and safety of TACE procedures. Additionally, the development of better catheterization techniques and embolic agents has enhanced the effectiveness and outcomes of TACE.

Multidisciplinary approach to cancer treatment: TACE is often used as part of a multidisciplinary approach to treating liver cancer. It may be combined with other interventions, such as radiofrequency ablation, sorafenib therapy, or immunotherapy, to achieve better treatment outcomes.

The global TACE market includes various players, including medical device manufacturers, pharmaceutical companies, and healthcare providers offering TACE equipment, drugs, and related services. Additionally, research and development activities are continually focused on improving the effectiveness and safety of TACE procedures and developing innovative embolic agents and drug formulations.

This report presents a comprehensive overview of the global Transarterial Chemoembolization (TACE) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Chemotherapeutic Agents
• Radio Therapeutic Agents
• Drug-eluting Particles
• Others

Segment by Application

• Hospitals
• Clinics
• Cancer Research Centers

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Transarterial Chemoembolization (TACE) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Clinics, Cancer Research Centers evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact